Filter
708
Filtered Results: 708
Text search:
Licensed
pharmaceutical
products
Featured
Recommendations
65
New Publications
181
Language
Document type
No document type
294
Studies & Reports
184
Guidelines
109
Manuals
57
Strategic & Response Plan
40
Training Material
9
Fact sheets
9
Situation Updates
5
Resource Platforms
1
Countries / Regions
Global
37
Kenya
30
India
17
Nigeria
16
South Africa
14
Uganda
14
Ethiopia
14
Ghana
13
Western and Central Europe
12
Liberia
12
Sierra Leone
11
Rwanda
10
Zimbabwe
9
Philippines
9
Latin America and the Carribbean
9
Nepal
8
Ukraine
8
Tanzania
8
Zambia
8
Africa
7
Eastern Europe and Central Asia
7
Bangladesh
7
Malawi
6
Myanmar / Burma
6
Syria
5
West and Central Africa
5
South–East Asia Region
5
East and Southern Africa
5
Thailand
4
Cambodia
4
Namibia
4
Botswana
4
Benin
3
Laos
3
Senegal
3
Asia
3
Middle East and North Africa
3
Indonesia
3
Eswatini/ Swaziland
3
North Macedonia
2
Tajikistan
2
Cameroon
2
Burkina Faso
2
Mozambique
2
Congo, Democratic Republic of
2
Western Pacific Region
2
North America
2
United Kingdom
2
Eastern Europe
2
Timor Leste/ East Timor
1
Serbia
1
Lesotho
1
Kazakhstan
1
Iran
1
Albania
1
Kyrgyzstan
1
Uzbekistan
1
Mongolia
1
Bulgaria
1
Guinea
1
Armenia
1
Haiti
1
Venezuela
1
Gabon
1
Vietnam
1
Brazil
1
Moldova
1
Russia
1
Sudan
1
Georgia
1
Mali
1
Angola
1
South Sudan
1
Somalia
1
Pakistan
1
Authors & Publishers
Publication Years
Category
Countries
264
Clinical Guidelines
70
Public Health
50
Key Resources
27
Pharmacy & Technologies
24
Women & Child Health
20
Capacity Building
4
Toolboxes
AMR
83
Pharmacy
71
COVID-19
47
Mental Health
30
NTDs
30
TB
28
HIV
27
Planetary Health
23
Rapid Response
22
Health Financing Toolbox
19
Caregiver
18
Global Health Education
17
Conflict
15
NCDs
13
Ebola & Marburg
9
Specific Hazards
5
Refugee
3
Disability
3
Polio
2
Natural Hazards
1
Social Ethics
1
WHO needs US$2.54 billion to provide life-saving assistance to millions of people around the world facing health emergencies. WHO’s Health Emergency Appeal is a consolidation of WHO’s priorities and financial requirements for 2023 to carry out health interventions in emergency and humanitarian r...
The WHO document "Integrating the prevention and control of noncommunicable diseases in HIV/AIDS, tuberculosis, and sexual and reproductive health programmes: implementation guidance" provides a framework for integrating noncommunicable diseases (NCDs) into existing health programs for HIV/AIDS, tub...
Monitoring financial protection and utilization of health services in Mongolia 2009-2018 is based on national representative household socioeconomic surveys. The study finds that between 2009 and 2018, despite ambitious health reforms, the incidence of catastrophic health spending and impoverishing ...
During the COVID-19 health crisis, community pharmacists had an enhanced role in supporting health-care systems that were overburdened by managing seriously ill patients. This study was undertaken to determine the patterns of community supply of antiviral and antibacterial agents from community phar...
For the global community to be able to achieve ambitious targets relating to the prevention and treatment of HIV, viral hepatitis and sexually transmitted infections (STIs), multiple types of medicines must be widely accessible to all affected populations in all countries.
The purpose of this rep...
This document sets out, therefore, to explain the socioeconomic value of investing in the fight against NTDs and highlights priorities for global investment attention. Our work was guided by the need not only for
additional funding and funders but also for the need to understand the current funding...
Integrating the prevention and control of noncommunicable diseases in HIV/AIDS, tuberculosis, and sexual and reproductive health programmes: implementation guidance
Guidelines for drinking-water quality: Fourth edition incorporating the first and second addenda
recommended
Guidance has been updated on a number of chemicals: asbestos, bentazone, chromium, iodine, manganese, microcystins, nickel, silver, tetrachloroethene and trichloroethene. Guidance has also been added for chemicals not previously assessed in the Guidelines: anatoxin-a and analogues, cylindrospermopsi...
A two-week mission was conducted by WASH and quality UHC technical experts from WHO headquarters and supported by the WHO Ethiopia Country Office (WASH and health systems teams) in July 2016, to understand how change in WASH services and quality improvements have been implemented in Ethiopia at nati...
In 2017, 3.6 million of the estimated 10 million people with TB worldwide were “missed” by national TB programmes (NTPs). Two thirds of them are thought to access TB treatment of questionable quality from public and private providers who are not engaged by the NTP. The quality of care provided i...
Using the WHO model list of essential medicines to update a national essential medicines list
Since 1977, WHO has been working with countries to design the package of essential medicines as an integral component of treatment within the continuum of care, developing and disseminating the Model List ...
The revised guidelines contain recommendations for specific administrative, environmental controls and respiratory protection, following the assessment made by an external group of experts convened as members of the Guideline Development Group. Moreover, these guidelines focus on interventions speci...
The report reflects on the trends, achievements and challenges in global health over the past decade during which Dr Margaret Chan has been Director-General of WHO. It discusses the role of WHO in dealing with such issues as the rise of noncommunicable diseases, leaps in life expectancy, and emergin...
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
This policy brief aims to provide a review of the current progress on implementing the Burkina Faso national action plan on AMR, identifies critical gaps, and highlights findings to accelerate further progress in the human health sector. The target audience includes all those concerned with implemen...
Version 1.1
Department of Mental Health and Substance Abuse
This document lays out economic arguments for investing in the Access to COVID-19 Tools Accelerator (ACT-Accelerator). Framed within an overall context that recognizes the broader human health and societal impacts of the COVID-19 crisis, ACT-Accelerator's Economic Investment Case argues that investm...
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
